SonoThera is an ultrasound-guided non-viral gene therapy platform that uses microbubble-mediated biophysical processes to selectively deliver nucleic acid loads of various types and sizes to different organs in the body non-invasively. Today, SonoThera announced the completion of a $60.75 million Series A round led by ARCH Venture Partners, with participation from Johnson & Johnson Innovation, Illumina, and Vertex Ventures.
This article is transferred from: https://www.itjuzi.com/investevent/13702593
This site is only for collection, and the copyright belongs to the original author.